The Complex Interplay of Antibiotic Use and Immune Checkpoint Inhibition

Overview

Journal Oncologist

Publisher Oxford University Press

Specialty Oncology

Date 2025 Feb 13

PMID 39945418

Authors

Lawrence W Wu

Ryan H Moy

Affiliations

Soon will be listed here.

References

Jing Y, Chen X, Li K, Liu Y, Zhang Z, Chen Y . Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy. J Immunother Cancer. 2022; 10(1). PMC: 8772460. DOI: 10.1136/jitc-2021-003779. View

Eng L, Sutradhar R, Niu Y, Liu N, Liu Y, Kaliwal Y . Impact of Antibiotic Exposure Before Immune Checkpoint Inhibitor Treatment on Overall Survival in Older Adults With Cancer: A Population-Based Study. J Clin Oncol. 2023; 41(17):3122-3134. DOI: 10.1200/JCO.22.00074. View

Perez-Cobas A, Artacho A, Knecht H, Ferrus M, Friedrichs A, Ott S . Differential effects of antibiotic therapy on the structure and function of human gut microbiota. PLoS One. 2013; 8(11):e80201. PMC: 3839934. DOI: 10.1371/journal.pone.0080201. View

Arbour K, Mezquita L, Long N, Rizvi H, Auclin E, Ni A . Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. J Clin Oncol. 2018; 36(28):2872-2878. DOI: 10.1200/JCO.2018.79.0006. View

Chalabi M, Cardona A, Nagarkar D, Dhawahir Scala A, Gandara D, Rittmeyer A . Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials. Ann Oncol. 2020; 31(4):525-531. DOI: 10.1016/j.annonc.2020.01.006. View

Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre M . The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science. 2018; 359(6371):104-108. PMC: 6707353. DOI: 10.1126/science.aao3290. View

Gopalakrishnan V, Spencer C, Nezi L, Reuben A, Andrews M, Karpinets T . Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2017; 359(6371):97-103. PMC: 5827966. DOI: 10.1126/science.aan4236. View

Cortellini A, Tucci M, Adamo V, Stucci L, Russo A, Tanda E . Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice. J Immunother Cancer. 2020; 8(2). PMC: 7646355. DOI: 10.1136/jitc-2020-001361. View

Elkrief A, Derosa L, Kroemer G, Zitvogel L, Routy B . The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor?. Ann Oncol. 2019; 30(10):1572-1579. DOI: 10.1093/annonc/mdz206. View

10.

Mohiuddin J, Chu B, Facciabene A, Poirier K, Wang X, Doucette A . Association of Antibiotic Exposure With Survival and Toxicity in Patients With Melanoma Receiving Immunotherapy. J Natl Cancer Inst. 2020; 113(2):162-170. PMC: 7850522. DOI: 10.1093/jnci/djaa057. View

11.

Jackson M, Goodrich J, Maxan M, Freedberg D, Abrams J, Poole A . Proton pump inhibitors alter the composition of the gut microbiota. Gut. 2016; 65(5):749-56. PMC: 4853574. DOI: 10.1136/gutjnl-2015-310861. View

12.

Sharma P, Goswami S, Raychaudhuri D, Siddiqui B, Singh P, Nagarajan A . Immune checkpoint therapy-current perspectives and future directions. Cell. 2023; 186(8):1652-1669. DOI: 10.1016/j.cell.2023.03.006. View

13.

Crespin A, Le Bescop C, de Gunzburg J, Vitry F, Zalcman G, Cervesi J . A systematic review and meta-analysis evaluating the impact of antibiotic use on the clinical outcomes of cancer patients treated with immune checkpoint inhibitors. Front Oncol. 2023; 13:1075593. PMC: 10019357. DOI: 10.3389/fonc.2023.1075593. View

14.

Hopkins A, Kichenadasse G, McKinnon R, Abuhelwa A, Logan J, Badaoui S . Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150. Br J Cancer. 2021; 126(1):42-47. PMC: 8727569. DOI: 10.1038/s41416-021-01606-4. View

15.

Routy B, Le Chatelier E, Derosa L, Duong C, Alou M, Daillere R . Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2017; 359(6371):91-97. DOI: 10.1126/science.aan3706. View

16.

Guerrero P, Albarran V, Gonzalez-Merino C, Garcia de Quevedo C, Sotoca P, Chamorro J . Detrimental effect of an early exposure to antibiotics on the outcomes of immunotherapy in a multi-tumor cohort of patients. Oncologist. 2024; 30(2). PMC: 11883155. DOI: 10.1093/oncolo/oyae284. View

17.

Rashid M, Zaura E, Buijs M, Keijser B, Crielaard W, Nord C . Determining the Long-term Effect of Antibiotic Administration on the Human Normal Intestinal Microbiota Using Culture and Pyrosequencing Methods. Clin Infect Dis. 2015; 60 Suppl 2:S77-84. DOI: 10.1093/cid/civ137. View